Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Nov 25;50(12):2365-2375.
doi: 10.1093/ced/llaf341.

Mycosis fungoides: a review

Affiliations
Review

Mycosis fungoides: a review

Charlotte Sheern et al. Clin Exp Dermatol. .

Abstract

Mycosis fungoides (MF) is the commonest subtype of cutaneous lymphoma, characterized by the infiltration of malignant T-cell clones into the skin. It accounts for approximately 60% of all cutaneous T-cell lymphoma diagnoses. MF has three distinct clinical stages - patch, plaque and tumour - presenting most commonly on the buttocks, trunk and breast. The presentation often mimics common inflammatory dermatoses such as eczema and psoriasis. Despite numerous theories, the aetiology of MF remains mostly unknown. Since its first description in 1806, diagnosis has remained a challenge and requires careful clinicopathological correlation. Patients may require multiple skin biopsies, especially at the patch stage, to identify the characteristic epidermotropic infiltrates of small-to-medium-sized lymphocytes. First-line management involves skin-directed therapies such as topical corticosteroids and phototherapy. If these are unsuccessful, systemic medications such as interferon-α, oral bexarotene, methotrexate and novel antibody therapies are trialled. MF can also respond to localized radiotherapy, total skin electron beam therapy and haematopoietic stem cell transplantation. Despite being primarily a cutaneous lymphoma, MF can progress to involve other organs. This review provides a comprehensive overview of the epidemiology, clinical features, diagnosis and management of MF.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: K.M. is Deputy Editor of Clinical Experimental Dermatology. N.J.L. is a trustee of the British Association of Dermatologists. The remaining authors declare no conflicts of interest.

MeSH terms